Program Complete

The TREAT Program is complete. This website is scheduled to be archived and disabled by July 1, 2020. Please contact with any concerns or questions.

Raziel Study

This is a study to test this investigational drug, RZL-012. “Investigational” means the study drug being tested has not been approved by the United States Food and Drug Administration (FDA) and is not available for sale.

RZL-012 is a substance that is a synthetic, sterile drug produced under good manufacturing practice conditions, as per the requirements of the FDA. Based on studies in the laboratory and in humans it is believed that the drug works by transforming naturally occurring white fat tissue to a thermogenic tissue, which burns energy by generating heat and causing reduction of fat tissue thickness.